SVB Leerink Maintains Outperform on 89bio, Lowers Price Target to $29
SVB Leerink analyst Thomas Smith maintains 89bio (NASDAQ:ETNB) with a Outperform and lowers the price target from $50 to $29.
The Daily Biotech Pulse: Merck’s Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours:
5 Analysts Have This to Say About 89bio
Over the past 3 months, 5 analysts have published their opinion on 89bio (NASDAQ:ETNB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
BTIG Maintains Buy on 89bio, Lowers Price Target to $24
BTIG analyst Justin Zelin maintains 89bio (NASDAQ:ETNB) with a Buy and lowers the price target from $28 to $24.
89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia
89bio Inc (NASDAQ: ETNB)
McCormick, General Mills And 3 Stocks To Watch Heading Into Wednesday
Some of the stocks that may grab investor focus today are:
89bio Announces Proposed $75M Underwritten Public Offering
89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases,
89bio Pulls Back With Market — But Could The Stock Soar 250%?
89bio, Inc (NASDAQ: ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 500 plummeting over 2%.
Analyst Ratings for 89bio
89bio (NASDAQ:ETNB) has observed the following analyst ratings within the last quarter: